STOCK TITAN

Trevena, Inc. - $TRVN STOCK NEWS

Welcome to our dedicated page for Trevena news (Ticker: $TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Trevena's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Trevena's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.9%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.21%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.47%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
covid-19
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
partnership
Trevena, Inc.

Nasdaq:TRVN

TRVN Rankings

TRVN Stock Data

7.56M
18.10M
0.92%
7.95%
0.62%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CHESTERBROOK

About TRVN

trevena, inc. is a clinical stage biopharmaceutical company that discovers, develops, and intends to commercialize innovative therapies that use a novel approach to target g protein coupled receptors, or gpcrs. we are dedicated to providing value to patients and healthcare providers by improving patient outcomes and reducing healthcare costs. we have identified four biased ligand drug candidates: trv130, an fda-designated breakthrough therapy, is currently in phase 3 testing for the intravenous treatment of acute moderate to severe pain; trv027 was evaluated in a phase 2b study for the treatment of acute heart failure; trv734 has completed phase 1 testing for oral treatment of acute and chronic pain; and trv250 is in preclinical development for the treatment of migraine. in addition, trevena has an early stage portfolio of drug discovery programs currently in lead optimization.